KOSDAQCosmetics123330

Genic

₩14,550▲ 0.34%2026-11-18 close
Market Cap
₩115.9B
Turnover
₩800M
Volume
60K
Shares out.
8M
PER
3.9×
PBR
1.8×
EPS
₩3,613
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Profit Recovery Driven by Hydrogel Mask Demand

Genic's profit recovery, led by hydrogel mask demand, moved from losses in 2023 to a larger profit in 2025, and quarterly sales rose for three straight quarters through Q3 2026.

  1. 1

    On a DART-disclosed basis, 2025 sales were KRW 78.2 billion (up 56.7% year on year) and operating profit was KRW 15 billion (up 148.6%), the largest year in 2022–2025.

  2. 2

    Q3 2026 sales reached KRW 52.8 billion, rising for three straight quarters, while operating profit was KRW 7.63 billion, down 23.6% from the prior quarter.

  3. 3

    A September 2026 press report cited a 132% line utilization rate for hydrogel masks and a planned October capacity expansion.

  4. 4

    Face hydrogel mask products accounted for 81% of Q2 2026 sales, indicating high product concentration.

  5. 5

    As profit grew, the share price relative to earnings has moved lower, while cash dividends remain modest.

02

Business structure

Genic is a cosmetics manufacturer whose core product is hydrogel mask packs, and its business centers on OEM and ODM production for customer brands rather than its own labels.

A May 2026 securities report noted that the company began with its own brands, but OEM and ODM work has been the main business since around 2020.

According to a broker-data aggregator, face hydrogel mask products made up 81% of Q2 2026 sales, followed by basic skincare at 7%, essence masks at 5%, eye hydrogel masks at 4%, and other items at 3%. Segment sales in KRW were not confirmed in disclosures, so only mix percentages are shown.

A June 2025 securities report attributed new orders to early passage of quality audits by global companies. The same report said the company remained the top-selling mask pack on Amazon in the United States and noted listings at Sephora, Boots in the UK, and Costco.

Customers include K-beauty brands and global brands, and because Genic manufactures on order, customer sales trends drive orders and utilization. A April 2025 securities analysis described basic skincare as at initial-order levels, but new product launches were seen raising the likelihood of sales growth.

Among listed cosmetics ODM companies, Cosmax and Kolmar Korea are the usual comparison points, while Genic is distinguished by its specialization in hydrogel mask production. The largest shareholder is Solbrain Holdings, with a 34.55% stake as of April 30, 2026.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩23.6B₩5.6B24.0%
2025Q4₩12.2B₩100M0.9%
2026Q1₩29.4B₩3.4B11.6%
2026Q2₩49.2B₩10B20.3%
2026Q3₩52.8B₩7.6B14.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩31.4B-₩3.2B-₩3.3B−10.1%−20.9%90.4%
2023₩28.1B-₩4B-₩4.4B−14.3%−38.2%102.9%
2024₩49.9B₩6B₩7.6B12.1%34.1%72.2%
2025₩78.2B₩15B₩18.9B19.1%46.0%37.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a DART-disclosed basis, sales fell 10.7% from KRW 31.4 billion in 2022 to KRW 28.1 billion in 2023, then rose 77.8% to KRW 49.9 billion in 2024 and 56.7% to KRW 78.2 billion in 2025, increasing for two straight years from 2024 through 2025. The largest year in 2022–2025 was 2025, and the smallest was 2023.

Operating results moved from an operating loss of KRW 3.17 billion in 2022 and KRW 4.02 billion in 2023, a continued loss with widening deficit, to an operating profit of KRW 6.02 billion in 2024, a turn to profit, and KRW 15 billion in 2025, up 148.6%.

Net profit attributable to controlling shareholders went from a net loss of KRW 4.41 billion in 2023 to KRW 7.56 billion in 2024 and KRW 18.9 billion in 2025. Net income including non-controlling interests matched the controlling-shareholder figure in every year from 2022 to 2025.

Operating margin moved from -10.1% in 2022 and -14.3% in 2023 to 12.1% in 2024 and 19.1% in 2025. Securities reports tied the 2024 turn to profit to rising hydrogel mask orders and higher utilization.

The debt ratio fell from 102.9% in 2023 to 37.7% in 2025, with year-end 2025 total equity of KRW 41 billion and total liabilities of KRW 15.5 billion. Operating cash flow rose from KRW 2.7 million... more precisely KRW 272 million in 2024 to KRW 20.7 billion in 2025.

On a quarterly basis, sales went from KRW 23.6 billion in Q3 2025 and KRW 12.2 billion in Q4 2025, down 48.4% from the prior quarter, to KRW 29.4 billion in Q1 2026, KRW 49.2 billion in Q2 2026, and KRW 52.8 billion in Q3 2026, rising for three straight quarters.

Operating profit fell to KRW 104 million in Q4 2025, then rose to KRW 3.41 billion in Q1 2026 and KRW 9.99 billion in Q2 2026, before declining 23.6% to KRW 7.63 billion in Q3 2026. Q3 2026 sales rose 124.2% year on year, but operating profit rose only 35.1%, so profit grew more slowly than sales.

Net profit attributable to controlling shareholders over the four quarters from Q4 2025 to Q3 2026 totaled KRW 28.3 billion.

05

Industry analysis

In cosmetics ODM, Genic's demand depends heavily on overseas sales growth in hydrogel mask packs. A May 2026 securities report cited mask pack exports and capacity expansion as reasons for expected strong 2026 results.

A June 2025 report noted several brands leading K-beauty's global expansion are in ongoing projects with the company. Demand strength can be read against capacity: a September 2026 press report cited 132% utilization and full operation of 15 production lines.

That points to orders exceeding installed capacity, so the pace of expansion sets the ceiling on sales. A 2025 securities report expected unit prices for orders to rise gradually as channels widened across Amazon in the United States and Europe, Sephora, and other retailers.

Among peers, Cosmax and Kolmar Korea are large ODM companies with broad product lines, while Cosmecca Korea is often compared on functional products. Genic is distinguished by hydrogel mask specialization, which makes it more sensitive to demand shifts in that single category. Where the industry stands in its cycle should be read alongside broker forecasts and reported results.

06

Outlook

A May 2026 securities report cited mask pack exports and capacity expansion as the main reasons for expected 2026 results. According to a June 2025 securities report, an additional expansion was completed in March 2025, and monthly production capacity was then up to 8.2 million units.

A September 2026 press report said a capacity expansion planned for October would raise the production ceiling. Whether sales and operating profit respond once the new capacity runs is the item to watch in upcoming results.

Q3 2026 sales of KRW 52.8 billion extended the three-quarter rise, but operating profit fell to KRW 7.63 billion, leaving a gap between sales growth and profit growth. Whether that gap reflects early expansion costs or product mix will show in the cost structure of the next annual report.

On the customer side, retail expansion through Amazon, Sephora, Boots in the UK, and Costco has been reported since 2025, and how much of it shows up in second-half volumes is the key question. New basic skincare launches were also reported as a factor that could change the sales mix.

No formal annual guidance has been issued, so the outlook is tied to the expansion schedule and reported order flow. The next annual report for 2026 will confirm full-year operating margin, which is the next checkpoint.

07

Valuation

PER
3.9×
PBR
1.8×
ROE
57.6%
EPS
₩3,613
BPS
₩8,080
Dividend per share
₩0

Genic's valuation reflects a period of rapid profit growth, with the price-to-earnings multiple moving lower as earnings expanded.

Operating profit rose 148.6% in 2025 and net profit attributable to controlling shareholders rose 149.7%, so the same share price implies a lower earnings multiple than in the early turn to profit. Immediately after the 2024 turn to profit, the earnings base was small and the multiple was high.

The price-to-book ratio measures the premium over net assets, and with year-end 2025 total equity rising to KRW 41 billion, the premium over book value has narrowed at a given share price.

Net profit attributable to controlling shareholders over the last four quarters totaled KRW 28.3 billion, and quarterly swings mean multiples should be read with caution. Cash returns to shareholders through dividends remain modest, and the earnings increase has been directed to capacity investment and operating funds.

The valuation direction will depend on whether earnings hold steady and where operating margin settles after expansion.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Demand Exceeding Capacity

Quarterly sales rose for three straight quarters from Q1 2026 to Q3 2026, reaching KRW 52.8 billion. A September 2026 press report cited 132% line utilization, indicating orders above installed capacity. A planned October expansion could raise the production ceiling.

Structural Margin Improvement

Operating margin improved from -10.1% in 2022 and -14.3% in 2023 to 12.1% in 2024 and 19.1% in 2025. Operating profit reached KRW 15 billion in 2025, up 148.6%. The pattern moved from continued losses to a turn to profit and a further recovery.

Stronger Financial Position

The debt ratio fell from 102.9% in 2023 to 37.7% in 2025. Operating cash flow rose to KRW 20.7 billion in 2025 from KRW 272 million in 2024. Total equity at year-end 2025 stood at KRW 41 billion.

09

Bear factors

High Quarterly Profit Volatility

Operating profit in Q4 2025 fell to KRW 104 million, down 98.1% from the prior quarter. Q3 2026 sales rose 124.2% year on year, but operating profit rose only 35.1%. Q3 2026 operating profit also fell 23.6% from the prior quarter, indicating uneven quarterly profit.

Dependence on Customers and Channels

Genic's results depend on customer orders under its OEM and ODM model. Face hydrogel mask products made up 81% of Q2 2026 sales, reflecting high product concentration. A shift in sales flows through specific overseas channels such as Amazon could affect orders and utilization directly.

Ownership Concentration and Capital Raising History

The largest shareholder held 34.55% as of April 30, 2026, a high concentration. In July 2024, a third-party allotment rights issue of KRW 3 billion was carried out with major shareholders. Cash returns to shareholders through dividends remain modest.

10

Risk factors

Customer Order Volatility

Most sales come from hydrogel mask ODM orders, so changes in customer purchasing feed directly into results. Sales fell 48.4% from the prior quarter in Q4 2025. Inventory adjustments or promotion timing at retail channels could also move quarterly results.

Capacity Execution and Quality Control

If expansion is delayed while utilization stays high, the company may be unable to fill orders. Conversely, right after expansion, costs and quality control can become heavier before new lines stabilize. The pace at which new lines feed into sales after Q4 2026 is the next point to monitor.

Ownership Structure and Dilution Risk

With the largest shareholder holding 34.55%, the free float is limited. The company raised funds through a third-party rights issue in 2024. If further capacity investment requires new funding, the shareholder structure could change depending on the financing method.

11

What to watch next

  1. Late March 2027 (2026 annual report deadline)

    Full-year 2026 sales and operating profit, including Q4, will be confirmed in disclosures. The key items are whether the quarterly sales rise continued into Q4 and whether full-year operating margin held near the 2025 level of 19.1%.

  2. Mid-May 2027 (Q1 2027 quarterly report; the 2026 Q1 report was filed May 14, 2026)

    Check how much new capacity is reflected in quarterly sales and whether operating profit grows in line with sales. Because Q3 2026 showed a gap between sales growth and profit growth, changes in cost structure matter.

  3. Mid-August 2027 (2027 half-year report; the 2026 half-year report was filed August 13, 2026)

    Review the sales mix by customer and channel, and whether the share of face hydrogel mask products changes. Also check how much new basic skincare launches contribute to the sales mix.

12

Overall view

Genic has shifted from an operating loss in 2023 to operating profit of KRW 15 billion in 2025, with hydrogel mask ODM at its core. On a DART-disclosed basis, 2025 sales were KRW 78.2 billion and net profit attributable to controlling shareholders was KRW 18.9 billion, the largest year in 2022–2025.

Quarterly sales rose for three straight quarters in 2026 to KRW 52.8 billion in Q3, but operating profit fell to KRW 7.63 billion in Q3, down from the prior quarter, showing quarterly profit volatility.

Bullish factors include demand exceeding capacity, improving operating margin, a lower debt ratio, and higher operating cash flow. Bearish factors include 81% concentration in face mask products, reliance on customer orders and overseas channels, and high ownership concentration with a past rights issue.

On valuation, profit growth has pushed the earnings multiple lower, which can be compared with historical levels. The next checkpoints are the full-year operating margin in the 2026 annual report and how quickly new capacity feeds into sales. This report does not provide an investment opinion or target price and is intended for information only.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.wisereport.co.kr
  2. butler.works
  3. kr.investing.com
  4. ket.kr
  5. news.nate.com
  6. goinsider.kr
  7. hanaw.com
  8. comp.fnguide.com
  9. hanaw.com
  10. news.nate.com
  11. mt.co.kr
  12. m.thinkpool.com
  13. g-enews.com
  14. m.thinkpool.com
  15. m.thinkpool.com
  16. m.thinkpool.com
  17. m.sedaily.com

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis